Analyst Daniel Brennan of TD Cowen maintained a Buy rating on Guardant Health, boosting the price target to $63.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Daniel Brennan has given his Buy rating due to a combination of factors including Guardant Health’s strong financial performance and positive outlook. The company’s second-quarter results exceeded expectations, with sales surpassing forecasts by 10% across its Oncology, Shield, and Biopharma segments. Additionally, the gross margin of 66% was higher than the consensus estimate of 62%, indicating improved operational efficiency.
Despite a delay in the release of Shield V2, management’s decision to prioritize resources for the Vanguard study launch reflects a strategic focus on long-term growth. The company’s robust sales growth, particularly in oncology and biopharma, coupled with increased guidance for 2025, suggests significant potential for future performance. Brennan believes that the strong quarterly results and optimistic management tone will continue to drive investor confidence in Guardant Health’s stock.